Netherlands-based Haga Teaching Hospital partners with physIQ and VitalConnect to continuously monitor cancer patients during treatment

THE HAGUE, Netherlands & CHICAGO–(BUSINESS WIRE)–Haga Teaching Hospital, physIQ, and VitalConnect announced today that cancer patients are being enrolled and monitored in a study that is evaluating how wearable biosensors and artificial intelligence-based analytics can augment clinical care for patients in treatment. The study is being funded by Janssen Pharmaceuticals (a Johnson & Johnson Company). In the investigator-initiated study, patients being treated with either erythrocyte transfusion or chemotherapy, either with or without immunotherapy, are provided VitalPatch® biosensors that collect and stream physiological data via physIQ’s pinpointIQ^TM platform. The goal of the study is to evaluate how continuous physiological data coupled with sophisticated personalized analytics can provide early clinical indication of adverse events sometimes associated with anti-cancer treatment.